| Keywords: |
cancer chemotherapy; gene mutation; mutation; clinical trial; interferon; unspecified side effect; clinical trials as topic; note; united states; methodology; neoplasms; imatinib; enzyme inhibition; history, 21st century; drug resistance; dasatinib; chronic myeloid leukemia; pyrimidines; cancer research; cancer resistance; oncogenes; drug dose escalation; protein kinase inhibitors; history, 20th century; drug research; cancer relapse; protein structure, tertiary; bcr abl protein; piperazines; nilotinib; bone marrow transplantation; leukemia, myelogenous, chronic, bcr-abl positive; awards and prizes; dna, complementary; academic achievement; blast cell crisis; sequence analysis, dna
|
